Altimmune Presents Data From Its Phase 2, MRI-Based Body Composition Sub-study Of Pemvidutide In Subjects With Overweight And Obesity
Altimmune Presents Data From Its Phase 2, MRI-Based Body Composition Sub-study Of Pemvidutide In Subjects With Overweight And Obesity
In an MRI sub-study of 67 subjects from the Phase 2 MOMENTUM obesity trial, 50 of whom were treated with pemvidutide for 48 weeks, the lean loss ratio, defined as the change in lean mass compared to the change in total mass, was 21.9%.
在MOMENTUm肥胖症2期試驗的MRI亞組研究中，共有67名受試者參與，其中50名接受了48周的pemvidutide治療，瘦體質量損失比例定義爲瘦體量變化與總體質量變化的比值爲21.9%。
Lean mass preservation was greater in subjects aged 60 years and older, in whom the lean loss ratio was only 19.9%. In addition to lean mass preservation, there was a preferential reduction of VAT, the adipose tissue associated with cardiovascular risk.
年齡在60歲及以上的受試者中，瘦體質量保留率更高，瘦體質量損失比例僅爲19.9%。除了瘦體質量的保留，還存在與心血管風險相關的脂肪組織——VAT的有選擇性減少。
At the 2.4mg dose of pemvidutide, VAT was reduced by 28.3% at Week 48 compared to a 19.5% loss in subcutaneous adipose tissue.
在2.4毫克劑量的pemvidutide中，與皮下脂肪組織的19.5%減少相比，第48周的VAt減少了28.3%。